brigatinib

Overview

Brigatinib, a next-generation “smart drug” and potent targeted therapy, represents a major advance in precision oncology for anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC). This oral small-molecule tyrosine kinase inhibitor overcomes crizotinib resistance through superior potency against ALK mutants and exceptional blood-brain barrier penetration, establishing superior progression-free survival and intracranial response rates as first-line therapy in NCCN/ESMO guidelines across US and European markets.

Generic name: Brigatinib
US Brand names: Alunbrig® (30 mg tablets for titration, 90 mg and 180 mg film-coated tablets)
Drug Class: Tyrosine kinase inhibitor (targeted therapy against ALK, ROS1, EGFR, MET, and other RTKs)
Route of Administration: Oral tablets (taken with food at consistent time)
FDA Approval Status: Accelerated approval May 14, 2017 (ALK+ NSCLC post-crizotinib); full approval March 6, 2020 (first-line ALK+ metastatic NSCLC) based on ALTA-1L phase 3 superiority trial

What Is It and How Does It Work? (Mechanism of Action)

Brigatinib selectively binds the ATP-binding pocket of ALK fusion kinases and resistance mutants via hydrogen bonding to the kinase hinge region (Met1199), preventing autophosphorylation and downstream activation of multiple oncogenic cascades essential for ALK-driven NSCLC proliferation, survival, and brain metastasis.

ALK inhibition (IC50 0.6 nM wild-type; G1202R 3.7 nM): Blocks EML4-ALK V1/V3 fusion autophosphorylation → inhibits RAS-RAF-MEK-ERK1/2 proliferation cascade and PI3K-PDK1-AKT-mTOR survival pathway
ROS1 inhibition (IC50 18 nM): Suppresses CD74-ROS1/SDC4-ROS1 fusions → STAT3/ERK phosphorylation blockade in ROS1+ NSCLC subset
Multikinase profile: EGFR L858R/T790M (IC50 15 nM), MET exon14 (IC50 4 nM), FAK (IC50 10 nM) → prevents bypass activation and EMT via Src-FAK-integrin signaling suppression
CNS efficacy: Uncharged macrocyclic scaffold + P-gp efflux pump inhibition → CSF:plasma AUC ratio 1.7 → therapeutic brain concentrations controlling leptomeningeal carcinomatosis
Immune effects: CSF1R inhibition → M2 macrophage repolarization; PD-L1 upregulation enhancing ICI synergy; BIM upregulation inducing mitochondrial apoptosis

FDA-Approved Clinical Indications

Brigatinib demonstrates FDA approval exclusively for biomarker-selected ALK fusion-positive NSCLC with preferred first-line status; emerging ROS1 data supports expanded access programs.

Oncological uses:
- Metastatic non-small cell lung cancer (NSCLC) with ALK gene rearrangements as detected by an FDA-approved companion diagnostic test (first-line therapy or following crizotinib)
Non-oncological uses: None

Dosage and Administration Protocols

Mandatory 7-day 90 mg lead-in dosing captures 80% early pulmonary adverse events; therapeutic 180 mg requires food co-administration doubling systemic exposure via reduced P-gp efflux.

Patient Population	Standard Dose	Frequency	Dose Adjustments
ALK+ NSCLC first-line	Days 1-7: 90 mg QD; Day 8+: 180 mg QD (with meal)	Continuous oral daily	Strong CYP3A inhibitor: 90 mg QD max; Grade ≥3 ILD: permanent discontinue
Moderate hepatic impairment (Child-Pugh B)	90 mg QD continuous	Same	Severe (C): contraindicated
Renal impairment (CrCl 30-60 mL/min)	No adjustment	Same	CrCl <30: reduce to 60 mg QD
Strong CYP3A inducer	Monitor closely	Same	No routine dose increase

Clinical Efficacy and Research Results

Pivotal ALTA-1L phase 3 trial (NCT02737501; n=275; 2020-2025 mature data) confirmed PFS superiority; intracranial landmark analyses establish CNS efficacy benchmark.

ALTA-1L (brigatinib vs crizotinib): Median PFS 24.0 vs 11.0 months (HR 0.49, p<0.0001); 12-month intracranial PFS 73% vs 43%; ORR 71% vs 60%
Baseline brain metastases (n=93): Intracranial ORR 78% (29/37) vs 29% (10/34); complete responses 23% vs 0%
ALK G1202R resistance: Post-next-gen TKI ORR 42%; median duration of response 11 months

Safety Profile and Side Effects

Black Box Warning: Severe, including fatal, pulmonary adverse reactions reported within 7 days of treatment initiation. Monitor closely during first 2 weeks; promptly evaluate new/worsening respiratory symptoms; permanently discontinue for Grade ≥3 ILD/pneumonitis.

Common Side Effects (>10%)

Adverse Event	Incidence	Management
Increased CPK	48% (15% Grade ≥3)	Baseline/weekly x1 month, hold >5x ULN; statin hold
Nausea	33%	Ondansetron 8 mg + metoclopramide PRN
Fatigue	29%	Scheduled rest; dose interruption Grade 3+
Cough/dyspnea	25%	O2 sat monitoring; CXR if persistent
Diarrhea	19%	Loperamide 4 mg then 2 mg PRN ≤16 mg/day

Serious Adverse Events

ILD/pneumonitis (3.7% Grade ≥3, 0.7% fatal; baseline CXR/PFTs; hold new/worsening dyspnea; permanent discontinue Grade 3+)
Bradycardia (7% symptomatic HR <60 bpm; hold if <50 bpm or symptomatic; resume 90 mg)
Hypertension (19% Grade ≥3; weekly BP first month, ACEi/ARB titration <140/90 mmHg)
CPK elevation/myopathy (15% Grade ≥3; hold >5x ULN with symptoms, resume 90 mg)

Current Research Areas (2025–2026)

CNS Dominance and Long-Term Survival: Updated findings from the ALTA-1L trial (May 2026) confirm brigatinib’s role as a first-line standard for ALK+ lung cancer. The research highlights a 76% reduction in the risk of disease progression or death specifically for patients with brain metastases, cementing its reputation for exceptional blood-brain barrier penetration.
Sensitizing Ovarian Cancer: A major 2026 breakthrough identifies brigatinib as a potent agent for treating high-grade serous ovarian cancer. By inducing a dual blockade of FAK and EPHA2 tyrosine kinases, it disrupts an “adaptive survival response” that cancer cells use to resist PARP inhibitors. This combination therapy has successfully induced tumor regression in models previously considered refractory.
Targeting “Triple-Mutant” EGFR: Research continues to validate brigatinib’s efficacy against the C797S/T790M/activating triple-mutant EGFR. Studies are evaluating brigatinib-based combinations as a strategy to restore sensitivity in patients who have progressed on third-generation inhibitors like osimertinib.
Vascular Synergy in Lung Cancer: Active Phase 1 trials are investigating the combination of Brigatinib and Bevacizumab. This research aims to determine if adding an anti-angiogenic agent can enhance the delivery of the TKI and improve progression-free survival in patients with recurrent ALK-rearranged tumors.
Biomarker-Based Combinations: Contemporary studies are refining the use of high FAK and EPHA2 levels as biomarkers to identify patients likely to respond to brigatinib outside of traditional CML or lung cancer indications. This research supports a personalized, “basket-trial” approach to treating aggressive, multi-drug resistant solid tumors.

Disclaimer: This information should be considered exploratory unless supported by definitive clinical evidence. While it represents significant frontiers in medical research, it is currently in the preclinical or early investigational phase and is not yet applicable to practical or professional clinical scenarios.

Patient Management & Practical Recommendations

7-day dose titration prevents 80% early pulmonary toxicity; weekly multidisciplinary monitoring first month sustains >90% dose intensity.

Pre-treatment Tests

ALK rearrangement testing (FDA-approved FISH/NGS assay)
Echocardiogram (LVEF >50%), ECG (QTcF <470 ms), PFTs/DLCO, CXR baseline
CPK, CMP (LFTs), CBC, TSH, urine/serum pregnancy test

Precautions During Treatment

Daily respiratory symptom diary Days 1-14; weekly CPK/BP first month → biweekly
Avoid strong CYP3A4 modulators; ECG if palpitations/syncope

Do’s and Don’ts

Do take 180 mg dose with substantial meal (≥600 kcal increases AUC 96%)
Do report new/worsening breathing difficulty, cough, fever within 24 hours
Don’t take with grapefruit juice or strong CYP3A inhibitors (ketoconazole)
Don’t drive/operate machinery if bradycardia symptoms (dizziness, syncope)

Legal Disclaimer

This guide provides general information about brigatinib and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult qualified thoracic oncologists for personalized recommendations considering ALK testing results, performance status, and comorbidity profile. Treatment decisions must balance efficacy against pulmonary/cardiac risks; this content neither endorses nor contraindicates specific therapeutic approaches.